All News

Strategies must be framed for addressing racial and geographic disparities in access for CAR T-cell and bispecific antibody therapy, according to the study authors.

Treatment with simple hysterectomy reduces the incidence of urinary incontinence compared with radical hysterectomy in patients with low-risk cervical cancer.

Investigators plan to reinitiate enrollment of patients with non-Hodgkin lymphoma as part of the phase 1a/1b NX-2127-001 trial.

Jae Park, MD, discussed the use of CAR T-cell therapy across the hematologic malignancies space.

Primary care physicians cannot afford to dismiss younger people who present with symptoms of cancer in the face of increasing cancer incidence, according to Monique Gary, DO, MSc, FACS.

Findings from a study highlight that 7/8 mismatched unrelated donor posttransplant cyclophosphamide may be a suitable alternative treatment option for those with graft-vs-host disease.

Helena A. Yu, MD, and Sandip P. Patel, MD, reviewed the use of patritumab deruxtecan, which was assessed in the phase 2 HERTHENA-Lung01 trial.

The use of novel agents like tarlatamab may be “interesting” among patients with small cell lung cancer in the relapsed setting, says Gregory Peter Kalemkerian, MD.

Jun Gong, MD, and Daneng Li, MD, discussed the most impactful trials coming from 2024 ASCO GI.

Reshma Jagsi, MD, DPhil, highlights disparities in hypofractionation, toxicity, and cardiac doses in radiotherapy for Black and Asian patients with breast cancer.

Findings from the INSITE trial support the Medical Imaging Drugs Advisory Committee’s positive opinion on pegulicianine for breast cancer surgery.

Data from the phase 3 VIALE-A trial showed continued responses during long-term follow-up for patients with newly diagnosed acute myeloid leukemia treated with venetoclax/azacitidine.

Findings from a phase 2 trial support the premise that activating the androgen receptor may elicit antitumor effects in patients with androgen receptor–positive, estrogen receptor–positive, HER2-negative breast cancer.

Developers also announced that they completed enrollment of patients with non–small cell lung cancer in the phase 2 THIO-101 trial.

In a recent Hot Topics article, reimbursement rates for Medicare physicians are discussed, and how it will impact their practice.

Treatment with rusfertide may reduce the use of phlebotomy and limit debilitating disease-related symptoms in patients with polycythemia vera based on findings from the phase 2 REVIVE trial.

The FDA approval of zanubrutinib plus obinutuzumab showed a benefit to patients with relapsed/refractory follicular lymphoma, according to Julie Vose, MD, MBA.

Patients with relapsed/refractory follicular lymphoma can now receive zanubrutinib plus obinutuzumab based on the data from the phase 2 ROSEWOOD trial.

The phase 3 ALPINE and ASCEND studies were used in the MAIC analysis assessing zanubrutinib vs acalabrutinib in relapsed/refractory chronic lymphocytic leukemia.

Results from the phase 3 CHECKMATE-901 trial led to the approval of nivolumab plus cisplatin and gemcitabine for patients with unresectable or metastatic urothelial carcinoma.

The DREAMM-8 trial assessing belantamab mafodotin plus pomalidomide/dexamethasone met the primary end point for those with relapsed/refractory multiple myeloma.

Linda E. Carlson, PhD, RPsych, discusses the recent updates from SIO/ASCO to the anxiety and depression guidelines for patients with cancer.

Findings from an open-label trial support the FDA approval of inotuzumab ozogamicin as a treatment for pediatric patients with relapsed/refractory acute lymphoblastic leukemia.

“Ultimately, we’re going to be able to see more patients, offer more precise surgery more efficiently, and that means just better outcomes for our patients here in the Intermountain West,” said Hilary McCrary, MD, MPH

Investigators are evaluating IO-202 in patients with newly diagnosed chronic myelomonocytic leukemia as part of a phase 1 dose expansion trial.

Investigators are assessing avutometinib plus defactinib as a treatment for those with low-grade serous ovarian cancer as part of the phase 3 RAMP 301 trial.

A recent clinical quandary focused on the diagnosis and treatment of blastic plasmacytoid dendritic cell neoplasm in a resource-limited setting.

Investigators will assess A2B530 as a treatment for patients with germline heterozygous HLA-A*02–positive colorectal cancer expressing carcinoembryonic antigen in the phase 1/2 EVEREST-1 trial.

Findings suggest that harnessing the tumoral node microenvironment may improve the ability to predict extracapsular nodal extensions in patients with oropharyngeal carcinoma.

Denosumab biosimilars have been approved by the FDA as Wyost and Jubbonti across various reference indications.